Theravance Biopharma TBPH Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $114.54M+8.2% | $105.9M+261% | $29.34M+125% | $13.03M+122% | -$58.33M-3.4% | ||
| $1.59M-2.0% | $1.63M-1.4% | $1.65M-1.4% | $1.67M-1.1% | $1.69M-1.1% | ||
| $18.1M-2.0% | $18.48M-6.8% | $19.82M-1.9% | $20.21M-4.0% | $21.04M-1.6% | ||
| —— | —— | —— | -$19.13M-113% | -$9M-17.5% | ||
| -$1.31M-501% | $326K-57.0% | $759K+75,800% | $1K-99.9% | $734K-2.4% | ||
| —— | —— | $8.28M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$502K+0.2% | -$503K+5.5% | ||
| $14K-85.3% | $95K— | —— | —— | —— | ||
| $4.11M+2.2% | $4.02M+1.4% | $3.96M-3.1% | $4.09M-4.5% | $4.28M-3.1% | ||
| -$7.65M-7.5% | -$7.12M-1,744% | -$386K-89.2% | -$204K-181% | $253K-61.7% | ||
| —— | —— | —— | $245.02M+653% | $32.53M+382% | ||
| $289.66M+16.7% | $248.22M+12.3% | $221.01M+56.6% | $141.15M+21.9% | $115.81M-17.7% | ||
| $206.38M+44.3% | $142.98M+21.7% | $117.5M-2.5% | $120.5M-6.1% | $128.39M-8.2% | ||
| -$83.91M+20.7% | -$105.87M-17.4% | -$90.19M-1,129% | -$7.34M— | —— | ||
| —— | —— | —— | —— | —— | ||
| $8.98M+123% | $4.03M+56.2% | $2.58M+12.2% | $2.3M+1.8% | $2.26M-14.9% | ||
| -$7.97M-145% | -$3.25M-53.1% | -$2.12M-1.3% | -$2.09M-28.1% | -$1.64M+34.5% | ||
| —— | —— | —— | —— | —— | ||
| $27.53M-1.3% | $27.88M+28.1% | $21.77M+142% | $9M+7,279% | $122K+11.9% | ||
| $3.11M+9.7% | $2.83M+23.0% | $2.3M-1.1% | $2.33M-6.3% | $2.48M-1.1% | ||
| -$7.65M-7.5% | -$7.12M-1,744% | -$386K-89.2% | -$204K-181% | $253K-61.7% | ||
| —— | —— | —— | -$502K+0.2% | -$503K+5.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$2.09M-6.2% | ||
| $1.84M-45.2% | $3.36M+462% | -$927K— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $232K-99.1% | $27.1M+1,806% | $1.42M-81.3% | $7.62M+1,006% | $689K-28.7% | ||
| —— | —— | —— | $204K-78.0% | $927K+31.1% | ||
| —— | $2.46M-2.4% | $2.52M-2.2% | $2.58M+0.7% | $2.56M+0.5% | ||
| $4.11M+2.2% | $4.02M+1.4% | $3.96M-3.1% | $4.09M-4.5% | $4.28M-3.1% | ||
| $1.59M-2.0% | $1.63M-1.4% | $1.65M-1.4% | $1.67M-1.1% | $1.69M-1.1% | ||
| $14K-85.3% | $95K— | —— | —— | —— | ||
| $10.67M+1.8% | $10.48M+37.9% | $7.6M-13.6% | $8.8M-6.5% | $9.41M-5.0% | ||
| $206.38M+44.3% | $142.98M+21.7% | $117.5M-2.5% | $120.5M-6.1% | $128.39M-8.2% | ||
| -$7.65M-7.5% | -$7.12M-1,744% | -$386K-89.2% | -$204K-181% | $253K-61.7% | ||
| —— | —— | —— | —— | —— | ||
| $27.53M-1.3% | $27.88M+28.1% | $21.77M+142% | $9M+7,279% | $122K+11.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Theravance Biopharma generate?
- Theravance Biopharma (TBPH) generated $323.5M in operating cash flow over the trailing twelve months.
- Where does Theravance Biopharma's cash flow data come from?
- Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
